Maternal anti-HLA class I antibodies are associated with reduced birth weight in thrombocytopenic neonates

Journal of Reproductive Immunology

Volumn 113, Issue , 2016, Pages 27-34

  Dahl, J ^a   Husebekk, A ^a   Acharya, G ^a,c   Flo, K ^a   Stuge, T B ^a   Skogen, B ^b   Straume, B ^a   Tiller, H ^a,c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b Norwegian National Unit for Platelet Immunology   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Alloimmunization; Antibodies; Birth weight; Neonatal thrombocytopenia; Placenta

Indexed keywords

HLA ANTIGEN CLASS 1; MATERNAL ANTIBODY; ALLOANTIBODY;

ADULT; ARTICLE; BIRTH WEIGHT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FETUS GROWTH; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NORWAY; OBSERVATIONAL STUDY; PLACENTA FUNCTION; PLACENTA WEIGHT; PREECLAMPSIA; PREGNANCY; PREGNANT WOMAN; PREMATURITY; PRIORITY JOURNAL; SMALL FOR DATE INFANT; BLOOD; COMPARATIVE STUDY; FETOMATERNAL TRANSFUSION; IMMUNOLOGY; LOW BIRTH WEIGHT; METABOLISM; PLACENTA; RETROSPECTIVE STUDY;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFANT, LOW BIRTH WEIGHT; ISOANTIBODIES; MATERNAL-FETAL EXCHANGE; PLACENTA; PREGNANCY; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84960358472     PISSN: 01650378     EISSN: 18727603     Source Type: Journal    
DOI: 10.1016/j.jri.2015.10.003     Document Type: Article

References (40)

1. Akalin E., et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin. J. Am. Soc. Nephrol.: CJASN 2008, 3:1160-1167.
2. Arck P.C., Hecher K. Fetomaternal immune cross-talk and its consequences for maternal and offspring's health. Nat. Med. 2013, 19:548-556.
3. Beiner M.E., et al. Risk factors for neonatal thrombocytopenia in preterm infants. Am. J. Perinatol. 2003, 20:49-54.
4. Buurma A., et al. Preeclampsia is characterized by placental complement dysregulation. Hypertension 2012, 60:1332-1337.
5. Davoren A., et al. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 2004, 44:1220-1225.
6. Dreyfus M., et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune thrombocytopenia working group. Blood 1997, 89:4402-4406.
7. Engineer N., Kumar S. Perinatal variables and neonatal outcomes in severely growth restricted preterm fetuses. Acta Obstet. Gynecol. Scand. 2010, 89:1174-1181.
8. Flo K., et al. A longitudinal study of the relationship between maternal cardiac output measured by impedance cardiography and uterine artery blood flow in the second half of pregnancy. BJOG: Int. J. Obstet. Gynaecol. 2010, 117:837-844.
9. Flo K., et al. Blood flow to the scarred gravid uterus at 22-24 weeks of gestation. BJOG: Int. J. Obstet. Gynaecol. 2014, 121:210-215.
10. Gramatges M.M., et al. Neonatal alloimmune thrombocytopenia and neutropenia associated with maternal human leukocyte antigen antibodies. Pediatr. Blood Cancer 2009, 53:97-99.
11. Hemachandra A.H., et al. The association between intrauterine growth restriction in the full-term infant and high blood pressure at age 7 years: results from the collaborative perinatal project. Int. J. Epidemiol. 2006, 35:871-877.
12. Kamphuis M.M., et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG: Int. J. Obstet. Gynaecol. 2010, 117:1335-1343.
13. Kapur R., et al. C-reactive protein enhances IgG-mediated phagocyte responses and thrombocytopenia. Blood 2015, 125:1793-1802.
14. Killie M.K., et al. Quantitative MAIPA: comparison of different MAIPA protocols. Transfus. Apheresis Sci. 2010, 43:149-154.
15. King K.E., et al. The role of HLA antibodies in neonatal thrombocytopenia: a prospective study. Tissue Antigens 1996, 47:206-211.
16. Kjeldsen-Kragh J., et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007, 110:833-839.
17. Lashley E.E., et al. Beneficial or harmful effect of antipaternal human leukocyte antibodies on pregnancy outcome? A systematic review and meta-analysis. Am. J. Reprod. Immunol. 2013, 70:87-103.
18. Lee P.C., et al. All chronic rejection failures of kidney transplants were preceded by the development of hla antibodies. Transplantation 2002, 74:1192-1194.
19. Lefaucheur C., et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol.: JASN 2010, 21:1398-1406.
20. Locke J.E., et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. American J. Transplant. 2009, 9:2136-2139.
21. Masson E., et al. Incidence and risk factors of anti-HLA immunization after pregnancy. Hum. Immunol. 2013, 74:946-951.
22. Moncharmont P., et al. HLA antibodies and neonatal alloimmune thrombocytopenia. Acta Haematol. 2004, 111:215-220.
23. Morin-Papunen L., et al. Maternal HLA immunization during pregnancy: presence of anti HLA antibodies in half of multigravidous women. Med. Biol. 1984, 62:323-325.
24. Mueller-Eckhardt C., et al. 348 Cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989, 1:363-366.
25. Nielsen H.S., et al. The presence of HLA-antibodies in recurrent miscarriage patients is associated with a reduced chance of a live birth. J. Reprod. Immunol. 2010, 87:67-73.
26. Norwegian Institute of Public Health, 2012. Fødsler i norge 2010.
27. Novotny V.M. Prevention and management of platelet transfusion refractoriness. Vox Sang. 1999, 76:1-13.
28. Redman C.W., Sargent I.L. Preeclampsia and the systemic inflammatory response. Semin. Nephrol. 2004, 24:565-570.
29. Regan L., et al. A prospective study of the incidence: time of appearance and significance of anti-paternal lymphocytotoxic antibodies in human pregnancy. Hum. Reprod. 1991, 6:294-298.
30. Saito S., et al. Serologic analysis of three cases of neonatal alloimmune thrombocytopenia associated with HLA antibodies. Transfusion 2003, 43:908-917.
31. Sargent I.L., et al. Maternal immune responses to the fetus in early pregnancy and recurrent miscarriage. Lancet 1988, 2:1099-1104.
32. Shehata F., et al. Placenta/birthweight ratio and perinatal outcome: a retrospective cohort analysis. BJOG: Int. J. Obstet. Gynaecol. 2011, 118:741-747.
33. Skjaerven R., et al. Birthweight by gestational age in norway. Acta Obstet. Gynecol. Scand. 2000, 79:440-449.
34. Skogen B., et al. Reconsidering fetal and neonatal alloimmune thrombocytopenia with a focus on screening and prevention. Expert Rev. Hematol. 2010, 3:559-566.
35. Starcevic M., et al. Neonatal alloimmune thrombocytopenia caused by anti-HLA-A24 alloantibodies. Acta Paediatr. 2010, 99:630-632.
36. Steinborn A., et al. Anti-fetal immune response mechanisms may be involved in the pathogenesis of placental abruption. Clin. Immunol. 2004, 110:45-54.
37. Thude H., et al. Neonatal alloimmune thrombocytopenia caused by human leucocyte antigen-B27 antibody. Transfus. Med. 2006, 16:143-149.
38. Tiller H., et al. Platelet antibodies and fetal growth: maternal antibodies against fetal platelet antigen 1a are strongly associated with reduced birthweight in boys. Acta Obstet. Gynecol. Scand. 2012, 91:79-86.
39. Tranquilli A.L., et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014, 4:97-104.
40. Zhang Q., et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005, 79:591-598.